

CIN : U24100DL2011PLC226781

# Fabino Life Sciences Ltd.

(An ISO 9001:2015 Certified Company)

Regd. Office: 105, 1st Floor, Barodia Tower, DDA Complex, Parshant Vihar, New Delhi-110085

May 24, 2022

To,  
Listing Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai -400001

Scrip Code-543444

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on 24<sup>th</sup> May, 2022.**

In continuation of our letter dated May 17, 2022, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements ) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in its meeting held on 24<sup>th</sup> May 2022, inter alia considered and approved the following;

1. Submission of Audited Financial Results for Half Year and Year ended March 31, 2022.
2. Appointment of M/s. B B Gusani And Associates (FRN: 140785W) as Internal Auditors of the Company for the F.Y. 2022-23.
3. Appointment of M/s. JNG & CO. Practicing Company Secretaries as Secretarial Auditors of the Company for the F.Y. 2022-23.
4. Appointment of Mr.Sumit Malik (DIN: 09615815) as an Additional Director of the Company with immediate effect and shall hold office till conclusion of upcoming General Meeting. He is not debarred from holding the office of Director by virtue of any order of SEBI or any other such authority.

The Audited Financial Results for the Half Year and Year ended March 31, 2022 , duly approved by the Board of Directors of the Company together with Statement of Assets and Liabilities and Independent Auditors Report thereon are enclosed.

The disclosure pursuant to point 3 & 4 of Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 is enclosed as **Annexure A & Annexure B**.

The Board Meeting commenced at 4.30 P.M. and concluded at 5:15 P.M.

The aforesaid results are also being disseminated on Company's website at <https://www.fabinolife.com/fabino-ipo/>


You are requested to kindly update above information on your record.

Thanking You,

**FOR FABINO LIFE SCIENCES LIMITED**

  
ATUL JAIN  
(DIRECTOR)  
DIN: 00004339





CIN : U24100DL2011PLC226781

# Fabino Life Sciences Ltd.

(An ISO 9001:2015 Certified Company)

Regd. Office: 105, 1st Floor, Barodia Tower, DDA Complex, Parshant Vihar, New Delhi-110085

May 24, 2022

To,  
Listing Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai -400001

Scrip Code- 543444


Dear Sir/Madam,

**Sub: Declaration on the Auditor's Report under Regulations 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements), 2015.**

Pursuant to provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby declare and confirm that the Auditor's Reports, on Financial Statements and Results for the Financial year 2021-22, which are being sent herewith, are unmodified and without any qualifications.

Thanking You,


**FOR FABINO LIFE SCIENCES LIMITED**



**ATUL JAIN  
(DIRECTOR)**

**DIN: 00004339**





CIN : U24100DL2011PLC226781

# Fabino Life Sciences Ltd.

(An ISO 9001:2015 Certified Company)


Regd. Office: 105, 1st Floor, Barodia Tower, DDA Complex, Parshant Vihar, New Delhi-110085

## ANNEXURE A

Sr. No.	Particulars	Disclosures
1.	Reason for change	Appointment
2.	Date of appointment & term of appointment	May 24, 2022.
3.	Brief profile	M/s. JNG & CO. is a Company Secretary Firm (Membership No. 55862, COP No. 20715) based out of Mumbai.
4.	Term of Appointment	For F.Y. 2022-23







CIN : U24100DL2011PLC226781

# Fabino Life Sciences Ltd.

(An ISO 9001:2015 Certified Company)

Regd. Office: 105, 1st Floor, Barodia Tower, DDA Complex, Parshant Vihar, New Delhi-110085

## ANNEXURE B

Sr. No.	Particulars	Disclosures
1.	Reason for change	Appointment
2.	Date of appointment & term of appointment	May 24, 2022.
3.	Brief profile	Mr. Sumit Malik aged 32 years, is a Non-Executive Director of our Company. He is working as an Engineer in a MNC and has done M.Tech..
4.	Disclosure of Relationship between Directors	Mr. Sumit Malik is not related to any of the Directors of the Company





**INDEPENDENT AUDITOR'S REPORT**

To Board of Directors of  
M/s Fabino Life Sciences Limited

Independent Auditors Report on Half year and year to date standalone financial results of M/s FABINO LIFE SCIENCES LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015

**Opinion**

1. We have audited the accompanying standalone financial results of M/s Fabino Life Sciences Limited (hereinafter referred to as "the company") for the year ended March 31, 2022 and the standalone statement of assets and liabilities and standalone statement of cash flows as at and for the year ended on that date, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('listing regulations').
2. In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:
  - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
  - (ii) give a true and fair view in conformity with recognition and measurement principles laid down in applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") and other accounting principles generally accepted in India, of the net profit (including other comprehensive income) and other financial information of the company for the year ended March 31, 2022, and the standalone statement of assets and liabilities and standalone statement of cash flows as at and for the year ended on that date.

**Basis for Opinion**

3. We conducted our audit in accordance with Standards on Auditing (SAs) specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India ("the ICAI"). Our responsibilities under those standards are further described in the 'Auditor's Responsibilities for the Audit of Standalone Financial Results' section of our report. We are independent of the company in accordance with the code of ethics issued by the ICAI together with ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and Rules made thereunder, and we have fulfilled our ethical responsibilities in accordance with the requirements with these requirements and the Code of Ethics. We believe that the audit evidences obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Board of Directors' Responsibilities for the Standalone Financial Results**

4. These standalone financial results have been prepared on the basis of the annual standalone financial statements. The company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the company and the standalone statement of assets and liabilities and standalone statement of cash flows in accordance with recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant issues thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other



irregularities; selection and application of accounting policies; making judgement and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate

internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give true and fair view and are free for material misstatement, whether due to fraud and error.

5. In preparing the standalone financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company is responsible for overseeing the financial reporting process of the Company.

### **Auditor's Responsibilities for the Audit of Standalone Financial Results**

7. Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from a fraud or error and consider material, if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.
8. As part of an audit in accordance with the SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedure responsive to those risks, and obtain audit evidence that is sufficient and appropriate to our basis of opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud involves collusions, forgery, intentional omissions, misrepresentations, or override of internal control.
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedure that are appropriate in circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and operating effectiveness of such controls.
  - Evaluate the appropriateness of the accounting policies used and reasonableness of accounting estimates and related disclosures made by the Board of Directors.
  - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on our audit evidences obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the company to continue as a going concern. If we conclude that material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidences obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
  - Evaluate the overall presentation, structure and content of financial results including the disclosures and whether the standalone financial results represent the underlying transactions and events in the manner that achieves fair presentation.

9. We communicate with those charged with governance of the company regarding, among other matters, the planned scope of timing of the audit and significant audit findings, including significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear our independence, and wherever applicable, related safeguards.

#### Other Matters

10. The standalone financial results include the results for the half year ended March 31, 2021 and March 31, 2022 being the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the respective financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

**FOR D G M S & CO.**

**Chartered Accountants**

Firm Regn. No. 0112187W



**Hiren J Maru**

Partner

Membership No. 115279

UDIN: 22115279AJMLTH6242



Date: 24<sup>th</sup> May 2022

Place: Mumbai



# FABINO LIFE SCIENCE LIMITED

CIN: U24100DL2011PLC226781

Registered Office: 105, 1ST FLOOR, D - BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085

## Statement of Standalone Audited Financial Results for the Half Year and Year Ended 31.03.2022

(Rupees in lakhs)

Particulars	Half Year Ended			Year Ended	
	31-03-2022	30-09-2021	31-03-2021	31-03-2022	31-03-2021
A	Date of start of reporting period	01-10-2021	01-04-2021	01-10-2020	01-04-2021
B	Date of end of reporting period	31-03-2022	30-09-2021	31-03-2021	31-03-2021
C	Whether results are audited or unaudited	Audited	Audited	Unaudited	Audited
<b>Part I</b>					
<b>I</b>	<b>Revenue From Operations</b>				
	Net sales or Revenue from Operations	215.26	204.81	237.88	420.07
<b>II</b>	<b>Other Income</b>	0.45	0.76	-	1.21
<b>III</b>	<b>Total Revenue (I + II)</b>	<b>215.71</b>	<b>205.57</b>	<b>237.88</b>	<b>421.28</b>
<b>IV</b>	<b>Expenses</b>				
(a)	Cost of materials consumed	0.12	0.39	0.16	0.51
(b)	Purchases of stock-in-trade	285.70	195.74	200.01	481.43
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(116.92)	-7.13	-4.07	(124.05)
(d)	Employee benefit expense	14.12	9.97	5.42	24.09
(e)	Finance Costs	0.19	0.19	-	0.38
(f)	Depreciation and amortisation expense	3.12	-	1.58	3.12
(g)	Other Expenses	17.60	11.61	13.57	29.20
	<b>Total expenses</b>	<b>203.93</b>	<b>210.76</b>	<b>216.68</b>	<b>414.69</b>
<b>V</b>	<b>Profit (loss) before Exceptional and Extraordinary</b>	<b>11.78</b>	<b>(5.19)</b>	<b>21.20</b>	<b>6.59</b>
<b>VI</b>	<b>Exceptional items</b>				
<b>VII</b>	<b>Share of Profit/(Loss) of Associates</b>				
<b>VIII</b>	<b>Profit (loss) before Tax (VII-VIII)</b>	<b>11.78</b>	<b>(5.19)</b>	<b>21.20</b>	<b>6.59</b>
<b>X</b>	<b>Tax Expense</b>				
(a)	Current Tax	1.84			1.84
	(Less):- MAT Credit				
	Current Tax Expense Relating to Prior years				
(b)	Deferred Tax (Asset)/Liabilities	0.04			0.04
<b>XI</b>	<b>Net Profit/Loss for the period from Continuing Operations (IX-X)</b>	<b>9.89</b>	<b>(5.19)</b>	<b>21.20</b>	<b>4.70</b>
<b>XII</b>	<b>Profit (Loss) from Discontinuing Operations</b>				
<b>XIII</b>	<b>Tax Expenses of Discontinuing Operations</b>				
<b>XIV</b>	<b>Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)</b>				
<b>XV</b>	<b>Profit (Loss) for the period (XI+XIV)</b>	<b>9.89</b>	<b>(5.19)</b>	<b>21.20</b>	<b>4.70</b>
<b>XVI</b>	<b>Other Comprehensive Income</b>				
a . i)	Amount of item that will not be reclassified to profit or loss				
ii)	Income tax relating to items that will not be reclassified to profit or loss				
b i)	Item that will be reclassified to profit or loss				
ii)	Income tax relating to items that will be reclassified to profit or loss				
<b>XVII</b>	<b>Total Comprehensive income</b>				
	<b>Total Comprehensive income [Comprising Profit for the Period ( After tax) and Other comprehensive income ] (XV+XVII)</b>	<b>9.89</b>	<b>(5.19)</b>	<b>21.20</b>	<b>4.70</b>
<b>XVIII</b>	<b>Details of equity share capital</b>				
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	210.00	210.00	120.00	210.00
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
<b>XIX</b>	<b>Reserves excluding revaluation reserve as per Balance Sheet</b>				
<b>XX</b>	<b>Earnings per share (Not Annualised for Half Year and Year ended)</b>	<b>0.47</b>	<b>-0.25</b>	<b>1.77</b>	<b>0.22</b>
(a)	<b>Earnings per share Continuing Operation ( Not Annualised for Half Year and Year ended )</b>				
	Basic earnings per share before extraordinary items	0.47	(0.25)	1.77	0.22
	Diluted earnings per share before extraordinary items	0.47	(0.25)	1.77	0.22
(b)	<b>Earnings per share Discontinuing Operation ( Not Annualised for Half Year and Year ended )</b>				
	Basic earnings per share after extraordinary items	-	-	-	-
	Diluted earnings per share after extraordinary items	-	-	-	-
(c)	<b>Earnings per share ( Not Annualised for Half Year and Year ended )</b>				
	Basic earnings per share before extraordinary items	0.47	(0.25)	1.77	0.22
	Diluted earnings per share before extraordinary items	0.47	(0.25)	1.77	0.22





**Notes:-****Notes to Standalone audited financials results for the year ended March 31, 2022.**

- 1 The above Audited financial results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taken on record by the Board of Directors at its meeting held on May 24, 2022 after being reviewed by the Audit Committee and have been Audited by Statutory Auditors of the Company who have issued an Audited report with unmodified opinion thereof.
- 2 The company has been listed on SME platform of Bse on 13th January 2022.
- 3 The company is engaged in only one business hence no information has been furnished in accordance with AS 17 on "Segment Reporting" issued by the Institute Of Chartered Accountants Of India
- 4 Figures for the half year ended on 31st March 2022 and 31st March 2021 are the balancing figures between the audited figures for the full financial year and the reviewed year to date figures for the half year ended on 30th Sept 2021
- 5 The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. (<https://www.fabinolife.com/fabino-ipo/>)
- 6 During the period Company has issued and allotted 9,00,000 equity shares Of Rs. 10 Each at price of Rs. 36 Per Share through Initial Public Offer Aggregating To Rs. 324.00 Lakhs. The Net issue proceedings excluding expenses is 280.34 Lakhs. The details of utilization of the net IPO proceeds is Mentioned Below:

Particular	As per Prospectus	Utilised till 31.03.2022	Difference
Part Repayment of Loans	25.00	25.00	-
Funding Working Capital Requirement	204.90	204.90	-
To fund expenditure for General Corporate Purposes	50.44	50.44	-
Total*	280.34	280.34	-

- 4 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

Date :- 24th May 2022  
Place :- Delhi





**FABINO LIFE SCIENCES LIMITED**

REGD. OFFICE : 105, 1ST FLOOR, D - BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085  
CIN: U24100DL2011PLC226781

**BALANCE SHEET AS AT 31ST MARCH, 2022**

(Rupees in Lakhs)

Particulars	Figures as at the end of current reporting period 2022	Figures as at the end of current reporting period 2021
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	210.00	120.00
(b) Reserves and Surplus	200.38	10.27
(c) Money received against share warrants	-	-
<b>(2) Share Application money pending allotment</b>		
<b>(3) Non-Current Liabilities</b>		
(a) Long-Term Borrowings	4.65	30.88
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	6.50	8.50
(d) Long Term Provisions	-	-
<b>(4) Current Liabilities</b>		
(a) Short-Term Borrowings	-	-
(b) Trade Payables	33.92	48.36
(c) Other Current Liabilities	4.24	6.24
(d) Short-Term Provisions	2.81	0.94
<b>Total Equity &amp; Liabilities</b>	<b>462.49</b>	<b>225.19</b>
<b>II.ASSETS</b>		
<b>(1) Non-Current Assets</b>		
<b>(a) Fixed Assets</b>		
(i) Tangible Assets	17.37	15.91
(ii) Intangible Assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible Assets under development	-	-
(v) Fixed assets held for sale	-	-
	17.37	15.91
(b) Non-current investments	-	-
(c) Deferred tax Assets (net)	0.96	1.00
(c) Long term loans and advances	-	-
(d) Other non-current assets	8.42	6.40
<b>(2) Current Assets</b>		
(a) Current investments	-	-
(b) Inventories	170.90	46.85
(c) Trade receivables	143.66	132.78
(d) Cash and cash equivalents	58.89	6.55
(e) Short-term loans and advances	62.29	15.69
(f) Other current assets	-	-
<b>Total Assets</b>	<b>462.49</b>	<b>225.19</b>

Date: 24th May 2022  
Place : Delhi





**FABINO LIFE SCIENCES LIMITED**

REGD. OFFICE : 105, 1ST FLOOR, D- BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085

CIN: U24100DL2011PLC226781

**CASH FLOW STATEMENT AS AT 31ST MARCH, 2022**

(Rupees in lakhs)

Particulars	Figures as at the end of current reporting period 2022	Figures as at the end of current reporting period 2021
<b>(A) Cash flows from operating activities</b>		
Profit for the year	4.70	3.02
- Finance costs	0.38	0.66
- Income tax Provision	1.89	1.24
<b>Adjustments for non-cash income and expenses:</b>		
- Depreciation & Amortisation	3.12	1.58
- Loss/(Profit) on sale/disposal of Fixed Assets	-	-
<b>Cash flow included in investing activities:</b>		
- Interest Income	-	-
<b>Changes in operating assets and liabilities:</b>		
- Decrease / (Increase) in Inventory	(124.05)	(17.43)
- Decrease / (Increase) in Trade Receivables	(10.89)	99.96
- Decrease / (Increase) in Other Current Assets	-	-
- Decrease / (Increase) in Other Non Current Assets	(2.02)	51.78
- Decrease / (Increase) in Short Term loans & Advances	(46.59)	(3.44)
- (Decrease) / Increase in Short Term Borrowings	-	-
- (Decrease) / Increase in Trade Payables	(14.44)	(166.12)
- (Decrease) / Increase in Other Current Liabilities	(2.00)	(13.22)
<b>Cash generated from operations</b>	(189.91)	(41.97)
Income tax paid	0.03	(3.02)
<b>Net cash from operating activities</b>	(189.88)	(44.99)
<b>(B) Cash flows from investing activities</b>		
Sale of Fixed Assets	-	-
Interest received / (Paid)	(0.38)	(0.66)
Purchase of Fixed Assets	(4.57)	(9.38)
<b>Net cash from investing activities</b>	(4.96)	(10.04)
<b>(C) Cash flows from financing activities</b>		
Proceeds from Share Capital	275.40	60.00
Proceeds/(Repayment) from Long-term borrowings	(26.23)	(8.76)
Proceeds/(Repayment) of other Current liabilities	(2.00)	(6.50)
<b>Net cash from financing activities</b>	247.17	44.74
<b>Net increase / (decrease) in cash and cash equivalents</b>	52.33	(10.29)
<b>Cash and cash equivalents at the beginning of year</b>	6.55	16.84
<b>Cash and cash equivalents at the end of year</b>	58.89	6.55
	(0)	0

Date: 24th May 2022

Place : Delhi

